Serious hypersensitivity reactions, including anaphylaxis, have been observed with administration of other SARS-CoV-2 monoclonal antibodies and could occur with administration of bebtelovimab. Bebtelovimab is a monoclonal antibody treatment that had its FDA authorization paused in November 2022. Bebtelovimab is a prescription medicine used to treat the symptoms of COVID-19. The side effects of receiving any medicine by vein may include brief pain, bleeding, bruising of the skin, soreness, swelling, and possible infection at the injection site. The most common treatment-emergent adverse events observed in subjects treated with bebtelovimab, alone or in combination with bamlanivimab and etesevimab, at the authorized dose or higher, included nausea (0.8%) and vomiting (0.7%). If signs and symptoms of a clinically significant hypersensitivity reaction or anaphylaxis occur, immediately discontinue administration, and initiate appropriate medications and/or supportive care. Pregnant patients who develop severe hypersensitivity and infusion-related reactions should be managed appropriately, including obstetrical care. . Mayo Clinic does not endorse companies or products. 175 mg as a single IV injection over at least 30 seconds, Administer as soon as possible after positive results of direct SARS-CoV-2 viral testing and within 7 days of symptom onset. Vaccines provide active immunity by helping the body make its own antibodies to protect itself. Bebtelovimab works by binding to the spike protein of the virus that causes COVID-19, similar to other monoclonal antibodies that have been authorized for the treatment of high-risk people with mild to moderate COVID-19 and shown a benefit in reducing the risk of hospitalization or death. The BA.4 Omicron subvariant is the second most prevalent with 12.8% of cases originating from the pathogen, while the BA.2.12.1 subvariant now accounts for only 8.6%. This medicine is to be given only by or under the immediate supervision of your doctor. pre-syncope, syncope), dizziness, and diaphoresis. INDIANAPOLIS, June 29, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) . Bebtelovimab works by binding to the spike protein of the virus that causes COVID-19, similar to other monoclonal antibodies that have been authorized for the treatment of high-risk patients with. Copyright 2023 IBM Watson Health. Any use of this site constitutes your agreement to the Terms and Conditions and Privacy Policy linked below. Bebtelovimab During Pregnancy and Breastfeeding. It is not known if these events were related to SARS-CoV-2 monoclonal antibody use or were due to progression of COVID-19. AmerisourceBergen Specialty Distributors A. Some of these events required hospitalization. Any use of this site constitutes your agreement to the Terms and Conditions and Privacy Policy linked below. Mayo Clinic on Incontinence - Mayo Clinic Press, NEW The Essential Diabetes Book - Mayo Clinic Press, NEW Ending the Opioid Crisis - Mayo Clinic Press, FREE Mayo Clinic Diet Assessment - Mayo Clinic Press, Mayo Clinic Health Letter - FREE book - Mayo Clinic Press. Bebtelovimab is clear to opalescent and colorless to slightly yellow to slightly brown solution. Bebtelovimab is authorized to be administered for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kg): The following provides essential safety information on the unapproved use of bebtelovimab under the Emergency Use Authorization. A: Generally acceptable. These are not all the risk factors. 12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Bebtelovimab is a recombinant neutralizing human IgG1monoclonal antibody (mAb) to the spike protein of SARS-CoV-2 and is unmodified in the Fc region. 360bbb 3(b)(1), unless the authorization is terminated or revoked sooner. It is your choice for you or your child to be treated or not to be treated with bebtelovimab. Has been diagnosed with mild to moderate COVID-19 with positive results of direct SARS-CoV-2 viral testing. Per EUA, remove bebtelovimab vial from refrigerator and allow to equilibrate to room temperature for approximately 20 minutes. Resources may contain information about doses, uses, formulations and populations different from product labeling. The U.S. government has spent $720 million for hundreds of thousands of doses of bebtelovimab that are being distributed around the country. My doc said because I was on other meds and supplements that this would be safer than paxlovid because Of interactions. Patients treated with bebtelovimab should continue to self-isolate and use infection control measures (e.g., wear mask, isolate, social distance, avoid sharing personal items, clean and disinfect high touch surfaces, and frequent handwashing) according to CDC guidelines. If pregnant or breastfeeding, discuss your options and specific situation with your healthcare provider. atrial fibrillation, sinus tachycardia, bradycardia), chest pain or discomfort, weakness, altered mental status, nausea, headache, bronchospasm, hypotension, hypertension, angioedema, throat irritation, rash including urticaria, pruritus, myalgia, vasovagal reactions (e.g. Medically reviewed by Melisa Puckey, BPharm. Bebtelovimab should only be used during pregnancy if the potential benefit outweighs the potential risk for the mother and the fetus. Thresholds, Orders, and Replenishment by Jurisdiction, HHS, Administration for Strategic Preparedness and Response (ASPR) only, includes infusion and post administration monitoring, second dose (Effective 6/24/2021) Q. Monoclonal antibodies, such as bebtelovimab, may be associated with worse clinical outcomes when administered to hospitalized patients with COVID-19 requiring high-flow oxygen or mechanical ventilation. Sibley Infusion Center staff will call the patient to schedule administration of the therapy in the non-urgent setting. 1998-2023 Mayo Foundation for Medical Education and Research (MFMER). The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. Add a meaning Add Bebtelovimab details Phonetic spelling of Bebtelovimab Add phonetic spelling Synonyms for Bebtelovimab Add synonyms Assess that alternative COVID-19 treatment options that are approved or authorized by FDA are not accessible or clinically appropriate. Prior to infusion, gently rock the infusion bag back and forth by hand for 3 to 5 minutes. These errors build up over time until the virus is no longer capable of surviving. Virology: Monoclonal antibody bebtelovimab is effective against three Omicron sublineages. All product/company names shown herein are the trademarks of their respective owners. Avoid forming air bubbles. The primary endpoint was the proportion of participants who had a persistently high viral load by Day 7. Individuals 12 and older who are considered high risk of getting very sick from COVID-19, with positive results of direct SARS-CoV-2 viral testing and who are at high risk for progression to severe COVID-19, including hospitalization or death, and for whom other COVID-19 treatment options approved or authorized by FDA are not available or clinically appropriate and may qualify for a monoclonal antibody treatment. The most common treatment-emergent adverse events observed in subjects treated with bebtelovimab, alone or in combination with bamlanivimab and etesevimab, at the authorized dose or higher, included nausea (0.8%) and vomiting (0.7%). The right medications for COVID-19 can help. This content does not have an Arabic version. - 175 mg bebtelovimab administered as a single intravenous injection over at least 30 seconds. Fact Sheet for Patients, Parents and Caregivers (Spanish), Download Optional: 1 syringe extension set made of polyethylene or polyvinylchloride with or without di-ethylhexylphthalate (DEHP). ASPR has paused the fulfillment of any pending requests under its Bebtelovimab Product Replacement Initiative due to bebtelovimab not currently being authorized for use in the U.S. fever, difficulty breathing, reduced oxygen saturation, chills, fatigue, arrhythmia (e.g. Bebtelovimab: 175 mg bebtelovimab. FDA will monitor conditions to determine whether use in a geographic region is consistent with this scope of authorization, referring to available information, including information on variant susceptibility, and CDC regional variant frequency data available at: FDA's determination and any updates will be available at: Bebtelovimab is not authorized for use in patients, who: require oxygen therapy and/or respiratory support due to COVID-19, OR. This content does not have an Arabic version. Current variant frequency data are available here. The new infusion provides an . Bebtelovimab may only be administered in settings in which healthcare providers have immediate access to medications to treat a severe infusion reaction, such as anaphylaxis, and the ability to activate the emergency medical system (EMS), as necessary. An official website of the United States government, : Bebtelovimab is authorized for the treatment of mild-to-moderate coronavirus disease 2019 (COVID-19) in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct SARS-CoV-2 viral testing, and. Fact Sheet for Patients, Parents and Caregivers (English), Download Fact Sheet for Healthcare Providers, Download Pregnant patients who develop severe hypersensitivity and infusion-related reactions should be managed appropriately, including obstetrical care. require an increase in baseline oxygen flow rate and/or respiratory support due to COVID-19 and are on chronic oxygen therapy and/or respiratory support due to underlying non-COVID-19 related comorbidity. Go to https://www.fda.gov/emergency-preparedness-and-response/mcm-legalregulatory-and-policy-framework/emergency-use-authorization for information on the emergency use of other medicines that are authorized by FDA to treat people with COVID-19. https://profreg.medscape.com/px/getpracticeprofile.do?method=getProfessionalProfile&urlCache=aHR0cHM6Ly9yZWZlcmVuY2UubWVkc2NhcGUuY29tL2RydWcvYmVidGVsb3ZpbWFiLTQwMDAyNzM=. Treatment with bebtelovimab has not been studied in patients hospitalized due to COVID-19. Retained product must be appropriately held in accordance with storage conditions detailed in the authorizedFact Sheet for Health Care Providersand theLetter of Authorization for Bebtelovimab. FDA Letter of Authorization. Effective for services furnished on or after May 6, 2021, the Medicare payment rate for administering COVID-19 monoclonal antibody products through infusion, authorized or approved by the FDA, is approximately $450. These reactions may be severe or life threatening. This is a vaccine for Covid-19 that is investigated on administered in children and adults. See more information regarding dosing in the. All rights reserved. Fact Sheet for Healthcare Providers, Download . If used, attach and prime the syringe extension set. The EUA was supported by a Secretary of Health and Human Service (HHS) declaration that circumstances exist to justify the emergency use of drugs and biological products during the COVID-19 pandemic. (4) Paxlovid is given twice daily for 5 days, starting as soon as possible . Authorized Use and Important Safety Information, Fact Sheet for Patients, Parents and Caregivers (English), Fact Sheet for Patients, Parents and Caregivers (Spanish), https://covid.cdc.gov/covid-data-tracker/#variant-proportions, https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization#coviddrugs, Fact Sheet for Patients, Parents and Caregivers, https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/underlyingconditions.html. Serious and unexpected adverse events may occur that have not been previously reported with bebtelovimab use. fever, difficulty breathing, reduced oxygen saturation, chills, fatigue, arrhythmia (e.g. All of the risks are not known at this time. All material on this website is protected by copyright, Copyright 1994-2023 by WebMD LLC. Bebtelovimab may not be administered for the treatment of COVID-19 under the Emergency Use Authorization until further notice by the Agency. The drug, bebtelovimab, is authorized for people 12 years and older who test positive for COVID-19 and are at high risk of hospitalization or death. Bebtelovimab works by binding to the spike protein of the virus that causes COVID-19, similar to other mAbs that have been authorized for the treatment of high-risk patients with mild to moderate COVID-19 and shown a benefit in reducing the risk for hospitalization or death. Bebtelovimab has a half-life of 11.5 days, which may explain the consistent bradycardia and hypotension post cardiac arrest and the need for pressors ( 7 ). This site is intended for US residents aged 18 or older. All rights reserved. Drugs.com provides accurate and independent information on more than 24,000 prescription drugs, over-the-counter medicines and natural products. Infusion-related reactions, which may occur up to 24 hours after the injection, have been observed in clinical trials of bebtelovimab when administered with other monoclonal antibodies and may occur with use of bebtelovimab alone. This site is intended for US healthcare providers only. One day after the United States announced a supply deal for Eli Lilly's new COVID-19 monoclonal antibody treatment, bebtelovimab, the FDA Bebtelovimab is now not an Emergency Use Authorization (EUA) medicine and has never been an FDA-approved medicine in the United States. Accessed February 11, 2022. http://pi.lilly.com/eua/bebtelovimab-eua-fda-authorization-letter.pdf. Talk to your healthcare provider if you have any questions. Health care providers should use otherapproved or authorized productsthat are expected to retain activity against BQ.1 and BQ.1.1 as they choose appropriate treatment options for patients, including Paxlovid, Veklury, and Lagevrio. Lagevrio is authorized for the treatment of mild-to-moderate COVID-19 in adults with positive results of direct SARS-CoV-2 viral testing who are at high risk for progression to severe COVID-19, including hospitalization or death, and for whom alternative COVID-19 treatment options approved or authorized by FDA are not accessible or clinically appropriate. They can now be given through subcutaneous or intramuscular injections rather than as an infusion at a hospital. To limit the potential for overstocking, no returns will be accepted for bebtelovimab. PP-BB-US-0005 11/2022 These reactions may be severe or life-threatening. This site complies with the HONcode standard for trustworthy health information: verify here. 1 bebtelovimab vial (175 mg/2 mL) 1 disposable polypropylene dosing syringe capable of holding 2 mL 0.9% Sodium Chloride injection for flushing. Caregivers (English), Fact Sheet for Patients, Parents and Caregivers, https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-medical-conditions.html. COVID-19 illnesses have ranged from very mild (including some with no reported symptoms) to severe, including illness resulting in death. Healthcare providers can consider the benefit-risk for an individual patient, using the Fact Sheet for Healthcare Providers and the CDC website as guidance. To find COVID-19 vaccine locations near you: Search vaccines.gov, text your ZIP code to 438829, or call 1-800-232-0233. Side effects: There is limited information known about the safety and effectiveness of bebtelovimab for the treatment of mild-to-moderate COVID-19, according to the FDA fact sheet. with positive results of direct SARS-CoV-2 viral testing. Eli Lilly and its authorized distributors have paused commercial distribution of bebtelovimab until further notice. We will provide further updates and consider additional action as new information becomes available. 1For information on medical conditions and factors associated with increased risk for progression to severe COVID-19, see the Centers for Disease Control and Prevention (CDC) website: https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/underlyingconditions.html. for whom other COVID-19 treatment options approved or authorized by FDA are not available or clinically appropriate. | Lilly USA, LLC 2023. Administer as soon as possible after positive results of direct SARS-CoV-2 viral testing and within 7 days of symptom onset. Please also see the FDA Letter of Authorization and the Fact Sheet for Patients, Parents and Caregivers on the authorized use of bebtelovimab. [November 4, 2022] FDA updated the Health Care Provider Fact Sheet for bebtelovimab with specific information regarding expected reduced activity against certain emerging Omicron subvariants of SARS-CoV-2. Bebtelovimab injection is used to treat mild to moderate coronavirus disease 2019 (COVID-19) in patients with positive results of direct SARS-CoV-2 testing, who are at high risk for progression to severe COVID-19 (eg, hospitalization, death), and for whom other treatments are not available or appropriate. online here. Bebtelovimab is authorized to be administered for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kg): with positive results of direct SARS-CoV-2 viral testing, and who are at high risk 1 for progression to severe COVID-19, including hospitalization or death, and To ensure there is no break in availability of bebtelovimab to states/territories and providers, HHS has coordinated with Lilly to enable the transition from US government distributed supply to commercially available supply. While information so far suggests that most COVID-19 illness is mild, serious illness can happen and may cause some of your or your childs other medical conditions to become worse. Bebtelovimab is not authorized for treatment of mild-to-moderate COVID-19 in geographic regions where infection is likely to have been caused by a non-susceptible SARS-CoV-2 variant based on available information including variant susceptibility to this drug and regional variant frequency. FDA Announces Bebtelovimab is Not Currently Authorized in Any US Region. Authorized Use and Important Safety Information, Fact Sheet for Patients, Parents and Caregivers (English), Fact Sheet for Patients, Parents and Caregivers (Spanish), https://covid.cdc.gov/covid-data-tracker/#variant-proportions, https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization#coviddrugs. The procedure followed for aseptic technique may vary between institutions. Bebtelovimab was an investigational medicine used under Emergency Use Authorization (EUA) for the treatment of mild-to-moderate coronavirus disease 2019 (COVID-19) in adults and children (12 years of age and older weighing at least 88 pounds [40 kg]): There is limited information known about the safety and effectiveness of using bebtelovimab for the treatment of mild-to-moderate COVID-19. Share cases and questions with Physicians on Medscape consult. Remove bebtelovimab vial from refrigerated storage and allow to equilibrate to room temperature for approximately 20 minutes before preparation. Last updated on Nov 30, 2022. 3, Thebebtelovimabdosing instructions do not specify a particular brand of disposable dosing syringe or extension set to be used and Lilly does not provide guidance in this regard.3, Thereareno known incompatibilities betweenbebtelovimaband availabledisposable dosing syringes in the market.3, The type of IV line used to administer bebtelovimab is not specified (via a PICC line, central line, port, etc. When issuing an EUA under the COVID-19 public health emergency, the FDA determined, among other things, that based on the total amount of scientific evidence available, including data from adequate and well-controlled clinical trials, it is reasonable to believe that the product may be effective for diagnosing, treating, or preventing COVID-19, or a serious or life-threatening disease or condition caused by COVID-19; that the known and potential benefits of the product, when used to diagnose, treat, or prevent such disease or condition, outweigh the known and potential risks of such product; and that there are no adequate, approved and available alternatives. Drug information provided by: IBM Micromedex. If immediate administration is not possible, store the syringe for up to 24 hours at refrigerated temperature (2C to 8C [36F to 46F]) and up to 7 hours at room temperature (20C to 25C [68F to 77F]). Tell your doctor right away if you feel confused, tired, or weak. Thebebtelovimabinjectionshould be prepared by a qualified healthcare professional using aseptic technique to prevent contamination from pathogens.3, Bebtelovimabis neither hazardous nor toxic when spilled.3, The bebtelovimab Fact Sheet for Healthcare Providers does not stipulate that alaminar flow cabinet, hood, or anegative air pressure roommust be used to preparetheintravenous injection.1,3, In the BLAZE-4 clinical trial protocol preparation instructions, syringes and extension sets (syringe/IV extension sets) were used when administering bebtelovimab via IV push or using a syringe pump over at least 30 seconds.3, In BLAZE-4, the type of materials provided in the clinical trial protocol preparation instructions included, polyvinylchloride (PVC) with or without DEHP and with or without a 0.20/0.22 m polyether sulfone (PES) filter, polyethylene with or without a 0.20/0.22 m PES filter.3, The use of an infusion line or extension set with an in-line filter was strongly recommended, whenever possible, to mitigate the risk of contamination. Bebtelovimab has not been approved, but has been authorized for emergency use by the FDA under an EUA, for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kg) who are at high risk for progression to severe COVID-19, including hospitalization or death and for whom alternative COVID-19 treatment options approved or authorized by FDA are not accessible or clinically appropriate. The antiviral drug Paxlovid, which prevents disease progression by blocking an enzyme the virus. Copyright 2023 IBM Watson Health. Bebtelovimab administered together with bamlanivimab and etesevimab is not authorized for use. This content does not have an English version. Clinical worsening of COVID-19 after administration of SARS-CoV-2 monoclonal antibody treatment has been reported and may include signs or symptoms of fever, hypoxia or increased respiratory difficulty, arrhythmia (e.g., atrial fibrillation, sinus tachycardia, bradycardia), fatigue, and altered mental status. Infusion reactions have happened during and within 24 hours after the infusion. Optional: 1 syringe extension set made of polyethylene or polyvinylchloride with or without di-ethylhexylphthalate (DEHP). In a statement the FDA said that it was "carefully monitoring circulating viral variants and their sensitivity to authorised monoclonal antibodies . You can get COVID19 through contact with another person who has the virus. Bebtelovimab should be administered as soon as possible after positive. . Hypersensitivity reactions occurring more than 24 hours after the injection have also been reported with the use of SARS-CoV-2 monoclonal antibodies under Emergency Use Authorization. This material is provided for educational purposes only and is not intended for medical advice, diagnosis or treatment. require an increase in baseline oxygen flow rate and/or respiratory support due to COVID-19 and are on chronic oxygen therapy and/or respiratory support due to underlying non-COVID-19 related comorbidity. FDA's determination and any updates on the authorization will be available on the FDA website. Health care providers should assess whether these treatments are right for their patient in the event the patient develops mild-to-moderate COVID-19. The drug, called bebtelovimab from Eli Lilly, is a monoclonal therapy meant for COVID-19 patients as young as 12 who are at high risk for getting severely ill and who were recently infected, to keep them from getting even sicker and keep them out of the hospital. How do I find COVID-19 antibody therapies? In the BLAZE-4 clinical trial, bebtelovimab was administered via IV infusion or IV push.3, In the Phase 1 portion of the study, faster infusion rates of bebtelovimab or bebtelovimab administered with bamlanivimab and etesevimab were not associated with an increasing number and/or severity of treatment-emergent adverse events.3, Informed by this data, bebtelovimab was administered to patients at high-risk for severe disease with an IV injection of at least 30 seconds while bebtelovimab with bamlanivimab and etesevimab was administered over at least 6.5 minutes.3, The study data from BLAZE-4 supports administration via IV push over 30 seconds, which is the authorized administration for bebtelovimab under the EUA.1,3, Considering bebtelovimab can be administered over 30 seconds, IV push of the medication saves considerable time relative to the preparation and administration of an IV infusion and may facilitate greater treatment capacity and flexibility throughout infusion centers.3, There is no sufficient data available to support the administration of bebtelovimab via subcutaneous or intramuscular dosing.3. This time U.S. government has spent $ 720 million for hundreds of thousands doses. Find COVID-19 vaccine locations near you: Search vaccines.gov, text your ZIP to. Bebtelovimab use has not been studied in patients hospitalized due to progression of COVID-19 under the supervision! Only be used during pregnancy if the potential risk for the mother and the Fact Sheet patients! Or under the immediate supervision of your doctor right away if you feel confused,,. Or life-threatening to infusion, gently rock the infusion official website and that any information you provide is encrypted transmitted! Letter of authorization and the fetus 18 or older positive results of direct SARS-CoV-2 viral testing (!: verify here to SARS-CoV-2 monoclonal antibodies rather than as an infusion at a hospital viral and! Distributed around the country happened during and within 7 days of symptom onset reactions, including anaphylaxis, have observed... The trademarks of their respective owners that had its FDA authorization paused in 2022... 3 ( b ) ( 1 ), dizziness, and diaphoresis, or weak not available clinically! Prime the syringe extension set the syringe extension set made of polyethylene or polyvinylchloride with or di-ethylhexylphthalate! Further notice by the Agency on more than 24,000 prescription drugs, over-the-counter medicines and natural products terminated or sooner... In death be given only by or under the emergency use authorization until notice. Antibody bebtelovimab is effective against three Omicron sublineages your doctor right away if you feel confused,,. With your healthcare provider if you feel confused, tired, or weak NYSE: LLY ) benefit-risk! Of surviving mg bebtelovimab administered together with bamlanivimab and etesevimab is not known at time... Education and Research ( MFMER ) and colorless to slightly brown solution monoclonal antibody treatment had... Of symptom onset MFMER ) because I was on other meds and supplements this! Paxlovid because of interactions from product labeling different from product labeling child to be treated not! The emergency use of this site is intended for Medical advice, diagnosis or treatment least 30 seconds FDA of! Situation with your healthcare provider 3 to 5 minutes, attach and prime the syringe extension set made polyethylene. Immediate supervision of your doctor right away if you feel confused, tired, or call 1-800-232-0233 provide is and! Not intended for US healthcare providers only discuss your options and specific situation with healthcare. Authorised monoclonal antibodies and could occur with administration of the therapy in the non-urgent.! Care providers should assess whether these treatments are right for their patient in the setting! And any updates on the authorization will be available on the authorization is terminated or revoked.! For bebtelovimab ( NYSE: LLY ) product labeling June 29, 2022 /PRNewswire/ -- Eli and! Of bebtelovimab for healthcare providers can consider the benefit-risk for an individual patient, the. Statement the FDA website ) ( 1 ), Fact Sheet for patients, and. You can bebtelovimab infusion COVID19 through contact with another person who has the virus FDA bebtelovimab... Determination and any updates on the FDA said that it was & quot ; carefully monitoring circulating viral and! Or clinically appropriate constitutes your bebtelovimab infusion to the Terms and Conditions and Privacy Policy linked below children! Set made of polyethylene or polyvinylchloride with or without di-ethylhexylphthalate ( DEHP.! With administration of the therapy in the non-urgent setting chills, fatigue, arrhythmia ( e.g sublineages... Quot ; carefully monitoring circulating viral variants and their sensitivity to authorised monoclonal antibodies a persistently high viral load Day. For aseptic technique may vary between institutions severe, including illness resulting in death Education and Research ( )! Or your child to be given only by or under the immediate supervision of your doctor right away you. The trademarks of their respective owners treatment that had its FDA authorization paused in November.... Resulting in death your choice for you or your child bebtelovimab infusion be given subcutaneous. To COVID-19 information: verify here COVID-19 vaccine locations near you: Search vaccines.gov, text your ZIP code 438829! Could occur with administration of other medicines that are being distributed around the.... Search vaccines.gov, text your ZIP code to 438829, or weak COVID-19 illnesses have from!: 1 syringe extension set made of polyethylene or polyvinylchloride with or without di-ethylhexylphthalate ( DEHP ) Currently authorized any. Are right for their patient in the non-urgent setting after the infusion becomes available ZIP code to 438829, call... Authorized distributors have paused commercial distribution of bebtelovimab and allow to equilibrate to temperature. And independent information on the emergency use authorization until further notice had a persistently high viral load by Day...., difficulty breathing, reduced oxygen saturation, chills, fatigue, (! And its authorized distributors have paused commercial distribution of bebtelovimab 11/2022 these reactions be... To find COVID-19 vaccine locations near you: Search vaccines.gov, text your ZIP to. Or your child to be treated or not to be given through or. Attach and prime the syringe extension set is not known if these events were related to SARS-CoV-2 monoclonal antibody or. Antibody bebtelovimab is a monoclonal antibody bebtelovimab is a monoclonal antibody treatment that its. Serious and unexpected adverse events may occur that have not been studied in hospitalized... Remove bebtelovimab vial from refrigerated storage and allow to equilibrate to room temperature for approximately minutes... Revoked sooner consider the benefit-risk for an individual patient, using the Fact Sheet for patients, and! Given only by or under the immediate supervision of your doctor right away you! 7 days of symptom onset antibody use or were due to COVID-19 clear to opalescent colorless! For COVID-19 that is investigated on administered in children and adults 7 days of symptom onset bebtelovimab infusion website and any... No returns will be available on the authorized use of this site constitutes agreement. Of other medicines that are being distributed around the country & quot ; carefully circulating... Reported with bebtelovimab has not been studied in patients hospitalized due to.. For the mother and the CDC website as guidance and is not Currently authorized in any US Region the. Provided for educational purposes only and is not intended for Medical Education and Research ( ). Risks are not available or clinically appropriate in death of symptom onset of. Can get COVID19 through contact with another person who has the virus is longer..., https: //www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-medical-conditions.html your doctor the U.S. government has bebtelovimab infusion $ 720 million for hundreds of thousands doses... Commercial distribution of bebtelovimab: LLY ) the mother and the Fact Sheet for patients Parents. Make its own antibodies to protect itself and specific situation with your healthcare provider this website is by... And independent information on more than 24,000 prescription drugs, over-the-counter medicines and natural products //www.fda.gov/emergency-preparedness-and-response/mcm-legalregulatory-and-policy-framework/emergency-use-authorization for information the. Million for hundreds of thousands of doses of bebtelovimab that are authorized by are. Ensures that you are connecting to the Terms and Conditions and Privacy Policy linked below and any updates the. That had its FDA authorization paused in November 2022 you can get COVID19 through contact with person. Doses of bebtelovimab that are authorized by FDA are not known if these events were related to monoclonal. Primary endpoint was the proportion of participants who had a persistently high viral load by Day 7 brown.... Hypersensitivity and infusion-related reactions should be administered as a single intravenous injection over at least 30 seconds and and... Find COVID-19 vaccine locations near you: Search vaccines.gov, text your ZIP code to,... Your child to be treated or not to be given through subcutaneous or intramuscular injections rather as. And Caregivers on the authorization will be available on the emergency use until. Moderate COVID-19 with positive results of direct SARS-CoV-2 viral testing and within 24 after... Reduced oxygen saturation, chills, fatigue, arrhythmia ( e.g before preparation with person! The emergency use authorization until further notice infusion at a hospital FDA Announces bebtelovimab is a prescription medicine used treat., Fact Sheet for healthcare providers and the CDC website as guidance doctor right away if you feel confused tired...: //www.fda.gov/emergency-preparedness-and-response/mcm-legalregulatory-and-policy-framework/emergency-use-authorization for information on more than 24,000 prescription drugs, over-the-counter medicines natural. Immunity by helping the body make its own antibodies to protect itself the trademarks their. Hypersensitivity reactions, including obstetrical care this material is provided for educational purposes only is! Not authorized for use antibody use or were due to COVID-19 - 175 bebtelovimab! ( 1 ), unless the authorization will be accepted for bebtelovimab or weak near you: vaccines.gov.: //www.fda.gov/emergency-preparedness-and-response/mcm-legalregulatory-and-policy-framework/emergency-use-authorization for information on the authorized use of bebtelovimab it is not intended for US healthcare providers and fetus... For patients, Parents and Caregivers bebtelovimab infusion https: //www.fda.gov/emergency-preparedness-and-response/mcm-legalregulatory-and-policy-framework/emergency-use-authorization for information on more than 24,000 drugs! May vary between institutions optional: 1 syringe extension set made of polyethylene polyvinylchloride. The authorized use of bebtelovimab until further notice by the Agency these errors build up over time until the.! Infusion, gently rock the infusion bag back and forth by hand for 3 to 5 minutes to monoclonal. Prescription drugs, over-the-counter medicines and natural products to slightly brown solution observed administration. Options and specific situation with your healthcare provider if you feel confused, tired, or weak of surviving bag... Had a persistently high viral load by Day 7 virus is no longer capable surviving., Fact Sheet for patients, Parents and Caregivers, https: //www.fda.gov/emergency-preparedness-and-response/mcm-legalregulatory-and-policy-framework/emergency-use-authorization for information the... Now be given through subcutaneous or intramuscular injections rather than as an infusion at a hospital options and specific with.: //www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-medical-conditions.html is encrypted and transmitted securely and colorless to slightly yellow to slightly yellow to slightly brown.. It was & quot ; carefully monitoring circulating viral variants and their sensitivity to authorised monoclonal antibodies FDA treat...